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ABSTRACT 
Introduction: Cushing's disease (CD) is a complex endocrine disorder characterized 
by an increased risk of recurrence and persistence of hypercortisolism after initial 
transsphenoidal adenomectomy, a situation requiring alternative therapeutic 
measures. 
Case presentation: A 21-year-old female patient was admitted for weight gain with 
centripetal fat distribution, transient headache, hair thinning and psycho-emotional 
lability. Clinical examination revealed round facies, acne, purple-red striae, hirsutism 
with a Ferriman-Gallwey score of 20. The hormonal profile revealed high serum 
cortisol (of 283.1 ng/mL, normal:70-225 ng/mL) and high ACTH (Adrenocorticotropic 
Hormone) levels (of 260.6 pg/mL, normal: 7.2-63.3 pg/mL). The pituitary MRI 
(Magnetic Resonance Imaging) examination found a 4.3/4.4/6.2mm left paramedian 
microadenoma. The persistence of hypercortisolism after adenomectomy required 
GKRS (Gamma Knife radiosurgery). Four months after radiosurgery, complete 
remission of the disease was achieved and it was maintained at the last evaluation. 
At present, the patient is 20 weeks pregnant. 
Conclusions: Gamma Knife radiosurgery offers a high control rate of pituitary 
adenomas and a reasonable rate of remission of residual hypercortisolism after 
neurosurgical treatment. After surgery or GKRS, periodic monitoring is necessary for 
patients with CD due to the risk of pituitary insufficiency or relapse. 
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INTRODUCTION 
Cushing’s disease is a complex disorder, 
characterized by a series of symptoms such as 
central obesity, hypertension, diabetes, as well as 
psychiatric and neurocognitive changes, caused by 
an ACTH–secreting pituitary adenoma leading to 
cortisol hypersecretion [1]. 
The gold standard treatment for CD is 
transsphenoidal surgical excision of the tumour, 
which is often curative. 
However, there is a failure rate of 10 to 35% in 
reaching complete remission, while a proportion of 
patients also experience disease recurrence in time 
[2-6]. 
A second-line treatment used to achieve control 
of hypercortisolism is represented by targeted 
radiation of the sellar adenomatous tissue, the most 
reliable therapy being GKRS [7,8]. 
 
CASE PRESENTATION 
A 21-year-old female smoker, without significant past 
medical history, was admitted for weight gain of 20 
kg in the past two months with centripetal 
distribution, transient headache, hair thinning, 
sleeping disorders and psycho-emotional lability. 
Clinical examination revealed height of 160 cm, 
weight of 76 kg, BMI (Body Mass Index) of 29.68 
kg/m2, blood pressure of 125/85 mmHg, heart rate of 
64bpm, round facies, acne, purple-red striae and 
hirsutism with a Ferriman-Gallwey score of 20. The 
hormonal profile showed high serum cortisol levels 
of 283.1 ng/mL (normal: 70-225 ng/mL) with 
maintained circadian rhythm, high 24-hour urine 
free cortisol (UFC) of 456.61g/24h (normal: 50-190 
g/24h), non-suppression of cortisol after the 1 mg 
DXM (dexamethasone) suppression test (of 145.9 
ng/mL, normal 18 ng/mL), adequate suppression 
after the two-day, 8 mg DXM test, high ACTH level of 
260.6 pg/mL (normal: 7.2-63.3 pg/mL), high levels of 
DHEAS (Dehydroepiandrosterone-sulfate) and 
testosterone (Table 1). Pituitary function tests 
showed normal plasma gonadotropin levels, normal 
PRL (prolactin) and TSH (Thyroid Stimulating 
Hormone) of 0.51µUI/mL with low FT4 (Free 
Thyroxine) of 0.86 ng/dL (normal: 0.89-1.76 ng/dL). 
There were no changes in biochemical parameters. 
Pituitary MRI (Magnetic Resonance Imaging) 
examination described a left paramedian 
microadenoma of 4.3/4.4/6.2 mm in diameter. 
Treatment with 25 µg tyroxine daily was initiated. 
Transsphenoidal adenomectomy was performed 
one month later. A massive intraoperative 
haemorrhage did not allow the removal of the 
tumour, therefore GKRS at a dose of 25 Gy was 
performed three weeks later. Four months after 
radiosurgery, complete remission of the disease was 
achieved, which was maintained at the one-year 
post-radiosurgery evaluation (Tabel 1). MRI revealed 
the cystic transformation of the pituitary 
microadenoma. At present, the patient is 20 weeks 
pregnant. 
 
 
 
Parameter Before surgery After radiosurgery Normal limits Units 
Morning plasma 
cortisol 
283.1 176.2 70-225 ng/mL 
Plasma cortisol 11pm 148.9 74.9 50-165 ng/mL 
24-h urinary cortisol 456.61 52.8 50-190 g/24h 
ACTH 260.6 43.14 7.2-63.3 pg/mL 
Morning plasma 
cortisol* 
145.9 9.1 < 18 ng/mL 
Morning plasma 
cortisol** 
94.7  <50*** ng/mL 
DHEA-S 8.19 2.79 0.9-3.6 µg/mL 
Testosterone 1.22 0.66 0.3-1 ng/dL 
TSH 0.51 0.297**** 0.4-4 µUI/mL 
FT4 0.86 0.96**** 0.89-1.76 ng/dL 
 
 
Table 1: The endocrine parameters of a 21-year-old female patient diagnosed with Cushing’s disease: before surgery and post-
Gamma Knife radiosurgery. *after the 1mg overnight Dexamethasone suppression test; **after the two-day, 8 mg Dexamethasone 
suppression test;***more than50% reduction; 24-h= 24-hours; ACTH= Adrenocorticotropic Hormone; DHEA-S= 
dehydroepiandrosterone-sulfate; TSH=Thyroid Stimulating Hormone; FT4=Free Thyroxine; ****25 µg/day Thyroxine therapy. 
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Figure 1: Preoperative contrast-enhanced pituitary MRI of a 21-
year-old woman diagnosed with Cushing’s disease: 
microadenoma measuring 4/6.5mm. Coronal plane. 
 
DISCUSSIONS  
Cushing's disease remains a challenge in clinical 
practice, both in terms of diagnosis and treatment, 
especially for young patients [9-12]. Transsphenoidal 
adenomectomy, the first-line therapeutic option, is 
not always curative. Consequently, all patients 
should be informed that recurrence can occur in a 
delayed fashion and that annual endocrine testing 
should be done to track and confirm disease status 
[11-13]. In our patient’s case, the failure of 
transsphenoidal adenomectomy was due to an 
intraoperative complication consisting of massive 
haemorrhage in the nasal mucosa. Considering the 
age of the patient and the desire to obtain a 
pregnancy, GKRS was recommended. The low risk of 
pituitary insufficiency and the relatively rapid 
remission of hypercortisolism are the main 
arguments for GKRS in persistent postoperative CD 
[14]. In this case, after GKRS, the secondary 
hypothyroidism persisted and was adequately 
controlled by thyroxine replacement therapy. 
Generally, the secretor pituitary tumours are 
approached by neurosurgery, medical therapy in 
cases like acromegaly, prolactinoma (in this 
particular situation medical therapy is usually the 
first line), and Cushing’s disease while radiotherapy 
remains a final option due to slow rate of response 
and the risk of associated hypopituitarism [16,17,18]. 
In this particular case the effect was rapidly 
observed. The non-secretor pituitary tumours are 
referred to surgery only if mass effect is positive 
[19,20]. As final option in Cushing’s disease one time 
or two times bilateral adrenalectomy is done 
knowing the risk of lifelong adrenal insufficiency 
[21,22]. 
Menstrual disorders and infertility are common in 
CD patients [15]. In our patient’s case there were no 
changes in ovarian function before GKRS, except for 
a higher level of testosterone. The normalization of 
cortisol, testosterone and DEAS levels in less than 6 
months after GKRS allowed spontaneous pregnancy. 
Considering the therapy used in this case, it is 
advisable to carefully monitor pituitary function 
throughout pregnancy. 
 
CONCLUSIONS 
Gamma Knife radiosurgery offers a high control rate 
of pituitary adenomas and a reasonable rate of 
remission of residual hypercortisolism after 
neurosurgical treatment. Close follow-up is 
necessary for patients with CD due to the risk of 
possible relapse and pituitary insufficiency after 
surgery or GNRS. 
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